Last updated: 2026-09-06 18:54:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
MapLight Therapeutics, Inc. (MPLT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $13.79, with a market capitalisation of $605.69M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $9.10 to $40.43. This page covers its latest market performance, valuation, price trends and company information.
$605.69M | |
$13.03 | |
$40.43 | |
$9.10 | |
$13.14 | |
483.02K | |
-- | |
-- | |
$40.43 | |
$9.10 | |
-- | |
-- |
MapLight Therapeutics, Inc. (MPLT) last closed at $13.14 as of 2026-09-04 23:31:00, unchanged from the previous close of $13.14.
During the latest regular trading session, MPLT traded between $9.10 and $40.43, with a volume of 483.02K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, MapLight Therapeutics, Inc. (MPLT) moved from $12.59 to $13.79, representing a gain of 9.53% ($1.20).
The stock traded between $12.82 and $14.16 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 641.43 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 15.0%
MPLT is currently trading at $13.79, placing it 15.0% of the way from its 52-week low of $9.10 to its 52-week high of $40.43. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 133 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of MapLight Therapeutics, Inc. (MPLT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.